



Published in final edited form as:
J Clin Res Bioeth. ; 5(5): 195–.

Ethics Standards (HRPP) and Public Partnership (PARTAKE) to Address Clinical Research Concerns in India: Moving Toward Ethical, Responsible, Culturally Sensitive, and Community-Engaging Clinical Research

Tal Burt^{1,*}, Yogendra K Gupta², Nalin Mehta², Nagendra Swamy³, Vishwas⁴, and Marjorie A Speers⁵

¹Duke Clinical Research Unit & Duke Clinical Research Institute, Durham, NC, USA

²All India Institute of Medical Sciences, New Delhi, India

³Manipal Health Enterprises, Karnataka, India

⁴Revogenex Inc., Duluth, GA, USA

⁵Association for the Accreditation of Human Research Protection Programs, Washington, DC, USA

Abstract

Like other emerging economies, India's quest for independent, evidence-based, and affordable healthcare has led to robust and promising growth in the clinical research sector, with a compound annual growth rate (CAGR) of 20.4% between 2005 and 2010. However, while the fundamental drivers and strengths are still strong, the past few years witnessed a declining trend (CAGR –16.7%) amid regulatory concerns, activist protests, and sponsor departure. And although India accounts for 17.5% of the world's population, it currently conducts only 1% of clinical trials.

Indian and international experts and public stakeholders gathered for a 2-day conference in June 2013 in New Delhi to discuss the challenges facing clinical research in India and to explore solutions. The main themes discussed were ethical standards, regulatory oversight, and partnerships with public stakeholders. The meeting was a collaboration of AAHRPP (Association for the Accreditation of Human Research Protection Programs)—aimed at establishing responsible and ethical clinical research standards—and PARTAKE (Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment)—aimed at informing and engaging the public in clinical research.

The present article covers recent clinical research developments in India as well as associated expectations, challenges, and suggestions for future directions. AAHRPP and PARTAKE provide

Copyright: © 2014 Burt T, et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

*Corresponding author: Tal Burt, Duke Clinical Research Unit & Duke Clinical Research Institute, Box 3854, DUMC, 40 Duke Medicine Circle, Durham, NC 27710, USA, Tel: 919-668-4650; Fax: 919-684-1674; tal.burt@duke.edu.

etiologically based solutions to protect, inform, and engage the public and medical research sponsors.

Keywords

Ethics standards; Public awareness; Clinical research; India

Introduction

In June 2013, a group of local and international clinical research and public stakeholders gathered in New Delhi to tackle a unique challenge: the fortunes and prospects of clinical research in India, one of the most promising global clinical research environments, appeared to be in decline. Conference stakeholders included experts from industry, academia, regulatory bodies, and the private sector as well as representatives from patient advocacy and public activist groups, non-governmental organizations (NGO's), and the media. The scope of the representation was a reflection of the organizers' collective belief that medical research in general and clinical research in particular require collaboration of both professional and non-professional segments of society, a rare undertaking in usual practice, to understand the challenges facing the sector and to identify effective solutions.

Background

Clinical research in India

Motivation for global and Indian clinical research—India has powerful drivers and attractive capabilities favoring clinical research. Rapid increase in life expectancy along with increases in the prevalence and burden of chronic illness are not yet matched by the provisions of the healthcare system or indigenous medical research capabilities [1–3]. The aspirations of the rapidly emerging economy, on track to become the world's second-largest by 2050, indeed include becoming self-sufficient in providing care to its growing population and basing such care on home-grown, evidence-based research [4]. Ethnic differences in the genetically heterogeneous population may affect presentation and outcomes of interventions, making generalizations from studies done elsewhere difficult and providing a strong case for indigenous clinical research [2,5–8].

India offers many advantages likely to appeal to medical researchers: well-trained (including many returning, Western-trained) physicians and investigators, an English-speaking environment, treatment-naïve populations, large healthcare center catchment areas, access to world-class information technologies and data management infrastructure, competitive operational costs (40–60% reduction when compared with Western sites), and sustained economic growth [9]. A study in 2006 by Kearney found India second only to China on the Country Attractiveness Index for Clinical Trials (primarily on the basis of patient pool and cost efficiency); however, India was less attractive than most countries in terms of regulatory conditions, infrastructure, and environmental factors (Figure 1) [10]. Advantages also include a harmonized regulatory system with an auditable clinical trial registry [11]. In addition, collaboration with Western universities and research networks has contributed to

the establishment of high clinical research standards [12,13]. Notwithstanding the considerable potential and strengths, and after a 2003 regulatory overhaul (Schedule Y [14]) initially translating into robust growth (2005–2010), the clinical research sector has witnessed a decline in recent years (Figure 2) [15–19]. While India represents 17.5% of the world's population, it has conducted only 1.75% of the world's clinical trials (2749 of 157,327) and currently only conducts 1.08% of global trials (211 of 19,599 trials registered with ClinicalTrials.gov from January 1 to December 31, 2013) [20–21].

India's regulatory environment

The Indian clinical research environment has come under increased scrutiny by public activists and the media, and subsequently by the Indian Supreme Court for perceived unethical practices in the conduct of clinical trials (Table 1) [16,24,26,30,32,36–39]. A report by the Indian Parliamentary Standing Committee identified an understaffed and under-resourced Central Drugs Standard Control Organization (CDSCO), including deficiencies in enforcing regulations, “collusion” with industry sponsors, and claims of exploitation of Indian citizens by foreign pharmaceutical companies [40]. Lack of regulatory clarity and lengthy turnaround times for clinical trial approvals have deterred both local and foreign sponsors from conducting clinical trials in India and may have contributed to the reduction in the number of clinical trials in India since 2010 (Figure 2) [18,39]. On January 30, 2013, the Ministry of Health and Family Welfare of India issued an amendment to the Drugs and Cosmetics Act of 1940 and the Ministry of Law issued a set of guidelines on patient compensation that included the need to pay should an experimental drug fail to show the intended therapeutic benefit (including in cases where research participants are allocated to placebo interventions) (Table 2) [25,30], Human Research Protection Program (HRPP) Conference, June 29–30, 2013, New Delhi, India].

In total, 169 participants, including 39 speakers, representing all clinical research stakeholders gathered for the 2-day conference. Fourteen participants were from the United States, the United Kingdom, Taiwan, and Saudi Arabia, and the rest were from India. The various attendees represented industry (56) healthcare (48), academia (40), NGO, public and patient advocacy (16), and regulatory (9) stakeholders.

Understanding the challenges and their causes

On day 1, conference participants viewed interactive and targeted presentations; on day 2, the group participated in focused discussions aimed at identifying and understanding the causes of challenges and proposing tangible solutions. Three factors and respective deficiencies emerged as probable causes of the observed difficulties facing clinical research in India:

Ethical standards of clinical research—Recent widespread reports of violations suggest that research standards, especially those pertaining to the protection of human participants, may not be properly enforced (Tables 1 and 2) [19,22,23,26,33,34,36,38,40,41,48–50]. The responsibility of ensuring respect for and protection of study participants is the foundation of the partnership between the researcher and the human research participant. Several principles of importance have been identified as

essential to the ethical conduct of clinical trials: superiority of benefit over risk (beneficence), fairness in assignment and access (justice), and validity and freedom of bias (integrity) [51]. However, it is autonomy and respect, manifested in the adequacy of the informed-consent process and compensation for adverse outcomes, that appear to dominate the concerns of stakeholders [26,33,38,47].

Regulatory process—The regulatory system that governs clinical research in India has undergone significant revisions and acquired meaningful strengths in the first decade of the new millennium, including harmonization of global good clinical practice (GCP) regulations and the establishment of mandatory clinical trial registration [9,11,14]. In recent years, however, there have been numerous incidences of regulators having difficulty enforcing regulations due to inadequate staffing and resources, claims of industry bias, and lack of clarity and transparency (Tables 1 and 2) [39,40]. Criticism pointed to a lack of equitable and feasible regulations (e.g., determination of serious-adverse-event causality) that take into account sociocultural characteristics, diversity, and vulnerabilities [30,38,47]. There is also a need to ensure the quality of research training and conduct as well as compliance of investigators and research operators [13].

Public perceptions and engagement in clinical research—This encompasses the following:

Existence of cultural divides (professional, national, international) [12,16,24,49,52]

Impaired public awareness, comprehension, empowerment, engagement, and partnership in clinical research, with a substantial and an active portion of the population (15–25%) holding negative perceptions of clinical research and being distrustful of researchers and regulators [16].

Lack of transparency and impaired communication amongst professional and public stakeholders limits reconciliation of different perspectives and the ability to establish consensus, working relationships, and collaborations [53–55].

With holding important contributions that the public may provide as an active partner in the clinical research process (communicating therapeutic preferences; enhancing study design; helping with data collection; enforcing standards; and helping with research funding, lobbying, and public policy [53,54,56,57]).

While available data are not sufficient to establish causality, these recent challenges have been associated with a decline (–16.7% compound annual growth rate [CAGR]) in the number of clinical trials conducted in the 2010–2013 period after a promising growth of 20.4% in the preceding 5 years (Figure 2).

Etiologically based solutions

Regulatory efforts together with the establishment of HRPPs and public awareness programs (e.g., PARTAKE [Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment]) complement each other's scope and strengths and offer

comprehensive, synergistic solutions to the complex problems facing clinical research in India.

Regulatory review and overhaul—Regulatory reorganization will ensure availability of resources and expertise to allow enforcement of regulations through education, training, accreditation, monitoring, and auditing of investigators and sites. Regulators should establish transparency and clarity regarding guidelines and responsibilities of clinical research professionals, and they should eliminate bias and conflicts of interest. The hoped outcomes of these actions are ensuring human research protection, verifying the quality of research applications and study operations, increasing trust in the regulatory system, reducing application turnaround times, and encouraging engagement and partnership by all stakeholders in clinical research. In the aggregate, these are also expected to lead to the generation of high-quality and credible research data.

Amendments proposed by regulators initially included provisions that were considered either not feasible or inconsistent with sound scientific methodology (e.g., compensation of all adverse events in clinical trials, expectation of therapeutic effect, attribution of placebo assignment to adverse events, expectation of ethics committees to determine compensation), yet these were decried by activists as containing insufficient protections for research participants [19,30,38,39]. By the end of 2013, the Chaudhury Expert Committee submitted recommendations that addressed earlier concerns [58].

ICMR (Indian Council of Medical Research), the national apex body to monitor clinical research in India is in the process of addressing clinical research challenges in India through collaboration with WHO (World Health Organization), Forum for Ethical Review Committees in the Asian & Western Pacific Region (FERCAP) and Strategic Initiative for Developing Capacity in Ethical Review (SIDCER).

HRPP initiatives—HRPP initiatives are a component of global AAHRPP (Association for the Accreditation of Human Research Protection Programs) efforts to promote responsible and ethical clinical research [59]. AAHRPP's mission is to protect human participants and enhance research quality through an accreditation process. The process aims to establish high, harmonized, and consistent standards of research operations, including standards for investigators, study teams, institutions, and ethics committees involved in clinical research. The process starts with self-assessment of compliance with a set of objective standards followed by onsite evaluation and council review by AAHRPP staff. The process emphasizes ongoing education and training, continuous process improvement, performance-based objective standards, and repeat accreditation. A robust informed-consent process (e.g., audio-video recording), monitoring, and auditing are examples of high standards that are involved. As of December 2013, India has 3 accredited institutions, China has 2, Singapore 1, South Korea 6, Taiwan 1, Mexico 1, and several additional institutions from emerging economies are in the process of seeking AAHRPP accreditation [60].

AAHRPP standards are grouped into 3 domains (Table 3): I) organization; II) institutional review board or ethics committee; and III) researcher and research staff. Each standard is

further divided into elements that provide additional details on specific accreditation requirements [60].

PARTAKE—The PARTAKE initiative started in India and then expanded to the United States and China, where surveys are underway [16]. Public awareness, perceptions, and consequent attitudes toward clinical research may impact regulatory policies, guide research priorities, and shape growth in the sector; however, distrust, lack of awareness, and misconceptions of clinical research have been identified as key barriers to participation in clinical trials [61–65]. The PARTAKE initiative is based on the premise that an informed, participating public is invaluable for the following ethical, methodological, and operational reasons:

A. Ethical: These can be divided into rights and obligations.

Rights: Participants in clinical research have the right to make informed decisions about participation in research [49,66,67] and are better positioned to protect their rights when they are knowledgeable of clinical research [68,69].

Obligations: Societies who desire and demand advanced therapeutics and individuals who are willing recipients of innovative treatments have an implied obligation to be part of the process that develops and approves them (i.e., becoming active participants, partners, and contributors to the process [53,54,67]).

Methodological: A wide and representative sample of participants in clinical research is essential to ensure adequate generalization of the findings to the population at large [57,70]. Informed persons and research participants could assist in enforcement of research standards (ethical and methodological) and increase the quality of data generated.

Operational: A key obstacle to medical progress is the limited participation in clinical research. This makes research more costly and less powerful in detecting meaningful therapeutic effects, and it delays the arrival of new treatments to those who need them [57,65,71–73].

The PARTAKE program includes 7 steps (Table 4), of which the first 2 have been initiated. Results of a pilot survey (albeit being limited to 1 Indian metropolitan [16]) suggest that the Indian public is aware of some key features of clinical research (e.g., purpose, value, voluntary nature of participation) and supports clinical research in general but is unaware of other key features (e.g., compensation, confidentiality, protection of human participants) and exhibits some distrust in the conduct and reporting of clinical trials [16]. Challenges facing the initiative and proposed solutions are summarized in Table 5.

Conclusions and Future Directions

The clinical research environment in India is challenged by a complex interplay of sociocultural, regulatory, ethical, economic, and scientific factors likely representing similar dynamics in other emerging economies. In a meeting of public, activist, media, government, academia, and clinical research industry stakeholders, a comprehensive effort was

undertaken to examine the sources of the difficulties and propose solutions. The principles and direction of AAHRPP (participant protection) and PARTAKE (public awareness) programs were identified, together with a regulatory overhaul, as complementary, synergistic, and crucial to any meaningful and lasting solutions. Etiologically based proposed strategies were focused on improving regulatory oversight, establishing research participant protection programs, and enhancing public awareness, empowerment, and engagement in clinical research. Ensuring a robust informed-consent process, promoting investigator education, establishing clarity and transparency of regulations, establishing community advocates, and creating a research participant bill of rights were some of the activities proposed by conference participants. These solutions should be carried out in a manner that is cognizant and respectful of sociocultural customs, diversity, and vulnerabilities of the population. These insights may be relevant to other emerging economies like China and Brazil, which (like India) have experienced a rapid introduction of modern research, and are looking to establish indigenous clinical research and bring the promise of affordable medical research and healthcare to their people.

Acknowledgment

The conference was organized by the Association for the Accreditation of Human Research Protection Programs, Medanta Duke Research Institute, and Medanta – The Medicity. It was supported by an educational grant from Pfizer, Inc. and the National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) under Award Number UL1TR001117. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The Indian Society for Clinical Research and the Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment society conducted parallel sessions on the second day of the conference.


References

1. Alzheimer's Disease International. World Alzheimer Report 2009. 2009
2. Cummings J, Reynders R, Zhong K. Globalization of Alzheimer's disease clinical trials. *Alzheimers Res Ther.* 2011; 3:24. [PubMed: 21861855]
3. World Health Organization. Geneva: Switzerland; 2004. The Global Burden of Disease: 2004 Update.
4. Dandona L, Katoch VM, Dandona R. Research to achieve health care for all in India. *Lancet.* 2011; 377:1055–1057. [PubMed: 21227496]
5. Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, et al. Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. *Am J Alzheimers Dis Other Demen.* 2012; 27:421–432. [PubMed: 22930699]
6. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol.* 2013; 9:106–118. [PubMed: 23296339]
7. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA.* 1997; 278:1349–1356. [PubMed: 9343467]
8. Singh PP, Singh M, Mastana SS. APOE distribution in world populations with new data from India and the UK. *Ann Hum Biol.* 2006; 33:279–308. [PubMed: 17092867]
9. Gupta YK, Padhy BM. India's growing participation in global clinical trials. *Trends Pharmacol Sci.* 2011; 32:327–329. [PubMed: 21489644]
10. Kearney AT. Make Your Move: Taking Clinical Trials to the Best Location. *Executive Agenda.* 2006:56–64.
11. Pandey A, Aggarwal AR, Maulik M, Gupta J, Juneja A, et al. The upgraded Clinical Trials Registry India: a summary of changes. *Indian J Med Ethics.* 2011; 8:186. [PubMed: 22106651]

12. Ali R, Finlayson A. Indox Cancer Research Network. Building capacity for clinical research in developing countries: the INDOX Cancer Research Network experience. *Glob Health Action*. 2012; 5
13. Burt T, Sharma P, Mittal S. Research Question, Study Design and Continuous Research Education and Training Exercises (CREATE) Program. *J Clin Prev Card*. 2012; 1:35–43.
14. Schedule, Y. Government of India. India: Drugs and Cosmetics Rules, 1945; 2005. Requirements and Guidelines for Permission to Import and/or Manufacture of New Drugs for Sale or to Undertake Clinical Trials.
15. Mansell P. India's clinical research market growing at 11–13%. *PharmTimes Online*. 2012
16. Burt T, Dhillon S, Sharma P, Khan D, Mv D, et al. PARTAKE survey of public knowledge and perceptions of clinical research in India. *PLoS One*. 2013; 8:e68666. [PubMed: 23874712]
17. Burt, T.; Hughes, L.; Kalali, A.; Doraiswamy, PM. *Global Clinical Trials for Alzheimer's disease*. San Diego, CA: Academic Press; 2014. Dementia clinical research in India.
18. <http://www.thehindu.com/sci-tech/health/policy-and-issues/post-stringent-norms-clinical-trials-in-india-plummet/article4639976.ece>.
19. Bhattacharjee Y. Public health. Clinical trials paused as India adopts new rules. *Science*. 2013; 341:327. [PubMed: 23888009]
20. <http://clinicaltrials.gov/ct2/home>
21. U.S. Census Bureau, International Population Reports WP/02. Washington, DC: U.S. Government Printing Office; 2002. Global Population Profile.
22. Sharda S. HC takes strong note of clinical trials on Indians without consent. *The Times of India*. 2012
23. Krishnan V. India as world's laboratory. *The Indian Express*. 2010
24. Nundy S, Gulhati CM. A new colonialism?--Conducting clinical trials in India. *N Engl J Med*. 2005; 352:1633–1636. [PubMed: 15843665]
25. Ministry of Health and Family Welfare. Drugs and Cosmetics (First Amendment) Rules, India. 2013
26. Press Trust of India. Only 45 of 2,868 clinical trial deaths compensated since 2005. *Business Standards*. 2013
27. Shah JY, Phadtare A, Rajgor D, Vaghasia M, Pradhan S, et al. What leads Indians to participate in clinical trials? A meta-analysis of qualitative studies. *PLoS One*. 2010; 5:e10730. [PubMed: 20505754]
28. Kraegen EW, James DE, Jenkins AB, Chisholm DJ. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. *Am J Physiol*. 1985; 248:E353–E362. [PubMed: 3883806]
29. Hashmi A. Pioglitazone suspension and its aftermath: A wake up call for the Indian drug regulatory authorities. *J Pharmacol Pharmacother*. 2013; 4:227–229. [PubMed: 24250197]
30. Sugarman J, Bhan A, Bollinger R, Gupta A. India's new policy to protect research participants. *BMJ*. 2013; 347:f4841. [PubMed: 23903456]
31. Gupta V, Goel A, Bhoi S. Medical research in India. *Lancet*. 2006; 368:644. [PubMed: 16920464]
32. National Human Rights Commission. NHRC issues notices to the Union Health Secretary, ICMR and DCGI calling for reports on allegations of fatal drug trials in the country, NHRC website. 2011
33. <http://www.thehindu.com/sci-tech/health/policy-and-issues/clinical-trial-of-untested-drugs-must-be-regulated-sc/article4956386.ece>.
34. Lakshmi R. India's drug trials fuel consent controversy. *The Washington Post*. 2012
35. Central Drugs Standard Control Organization. Draft Guidelines on Audio-Visual Recording of Informed Consent Process in Clinical Trial. 2014
36. Srinivasan S. Center for Studies in Ethics and Rights. Ethical concerns in clinical trials in India: an investigation. Centre for Research on Multinational Corporations website. 2009
37. Srinivasan S, Loff B. Medical research in India. *Lancet*. 2006; 367:1962–1964. [PubMed: 16782469]
38. Jesani A. New regulations on compensation for injury and death in drug trials. *Indian J Med Ethics*. 2013; 10:76–79. [PubMed: 23697484]

39. Chowdhury N. Poor definitions threaten drug trial safety in India. *Nat Med.* 2013; 19:15. [PubMed: 23295999]
40. Parliament of India, Rajya Sabha. Fifty-Ninth Report on the Functioning of the Central Drugs Standard Control Organization (CDSCO). 2012
41. Shetty P. Vaccine trial's ethics criticized. *Nature.* 2011; 474:427–428. [PubMed: 21697918]
42. Carroll JD. Is this the NIH Francis Collins wanted to create? *FierceBiotech.* 2013
43. Krishnan V, Koshy PK. US agency NIH scraps nearly 40 clinical trials in India. *LiveMint.* 2013
44. U.S. Food and Drug Administration. Ranbaxy Warning Letter. 2009
45. U.S. Food and Drug Administration. Wockhardt Limited Warning Letter. 2013
46. Brennan Z. Quintiles shuts phase I unit in India. Outsourcing-Pharma.com. 2013
47. Munshi R, Thatte U. Compensation for research related injury. *Perspect Clin Res.* 2013; 4:61–69. [PubMed: 23533985]
48. Mahaluxmivala N. Human subject protection in India - is it adequate? *Perspect Clin Res.* 2010; 1:15–20. [PubMed: 21829776]
49. Srinivasan S. Patient protection in clinical trials in India: some concerns. *Perspect Clin Res.* 2010; 1:101–103. [PubMed: 21814629]
50. Ramamurthy NV. Inept media trials of clinical trials. *Perspect Clin Res.* 2012; 3:47–49. [PubMed: 22701819]
51. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? *JAMA.* 2000; 283:2701–2711. [PubMed: 10819955]
52. Bhatt A. Government's role in shaping public perceptions about clinical research. *Perspect Clin Res.* 2012; 3:87–89. [PubMed: 23125958]
53. Institute of Medicine. *Public Engagement and Clinical Trials: New Models and Disruptive Technologies - Workshop Summary.* The National Academies Press; 2011.
54. Institute of Medicine. *Partnering with Patients to Drive Shared Decisions, Better Value, and Care Improvement - Workshop Proceedings.* The National Academies Press; 2013.
55. Institute of Medicine. *The National Academies Press; 2013. Sharing Clinical Research Data - Workshop Summary.*
56. Terry SF, Terry PF. Power to the people: participant ownership of clinical trial data. *Sci Transl Med.* 2011; 3:69cm3.
57. Michaels M, Weiss ES, Guidry JA, Blakeney N, Swords L, et al. "The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual". *J Cancer Educ.* 2012; 27:67–74. [PubMed: 21938600]
58. http://www.spggi.ac.in/sop/Action_RR_Choudhury_Committee__06.11.2013.pdf.
59. Speers MA. Making human research safe: why we cannot afford to fail. *Sci Eng Ethics.* 2005; 11:53–59. [PubMed: 15726999]
60. <http://www.aahrpp.org/learn/find-an-accredited-organization>.
61. Mills EJ, Seely D, Rachlis B, Griffith L, Wu P, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. *Lancet Oncol.* 2006; 7:141–148. [PubMed: 16455478]
62. Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. *Arch Intern Med.* 2002; 162:2458–2463. [PubMed: 12437405]
63. Jones JM, Nyhof-Young J, Moric J, Friedman A, Wells W, et al. Identifying motivations and barriers to patient participation in clinical trials. *J Cancer Educ.* 2006; 21:237–242. [PubMed: 17542716]
64. Markman M, Petersen J, Montgomery R. An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials. *J Cancer Res Clin Oncol.* 2008; 134:115–118. [PubMed: 17598129]
65. Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, et al. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. *Oncology.* 2008; 74:177–187. [PubMed: 18714166]

66. Kass NE, Myers R, Fuchs EJ, Carson KA, Flexner C. Balancing justice and autonomy in clinical research with healthy volunteers. *Clin Pharmacol Ther.* 2007; 82:219–227. [PubMed: 17410122]
67. Tinetti ME, Basch E. Patients' responsibility to participate in decision making and research. *JAMA.* 2013; 309:2331–2332. [PubMed: 23700165]
68. Shah K, Garg S. Patient advocacy groups: Need and opportunity in India. *Perspect Clin Res.* 2011; 2:4–7. [PubMed: 21584175]
69. <http://www.nami.org/>.
70. Landy DC, Brinich MA, Colten ME, Horn EJ, Terry SF, et al. How disease advocacy organizations participate in clinical research: a survey of genetic organizations. *Genet Med.* 2012; 14:223–228. [PubMed: 22261756]
71. Mackenzie IS, Wei L, Rutherford D, Findlay EA, Saywood W, et al. Promoting public awareness of randomised clinical trials using the media: the 'Get Randomised' campaign. *Br J Clin Pharmacol.* 2010; 69:128–135. [PubMed: 20233175]
72. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. *JAMA.* 2004; 291:2720–2726. [PubMed: 15187053]
73. Mudd J. Reach out to the people: Who better to educate a wary public about clinical research than the industry's own? 2007



Adapted from: **Make your Move: Taking Clinical Trials to the Best Location**, Kearney AT, 2006 [10]

Figure 1.
Most Attractive Global Locations for the Conduct of all Clinical Trials Outside the United States: 2006.




Figure 2.

ClinicalTrials.gov. All India Clinical Trials 2002–2013

Data were obtained from ClinicalTrials.gov on January 9, 2014. Methods: “Advanced Search” option was used. “India” entered in “Country” field. “First Received” field was used to include dates “From 01/01/.... To 12/31/....” for each year from 2002 through 2013. Compound annual growth rate (CAGR) was used for the periods 2005–2010 and 2010–2013 (years prior to 2005 were deemed to contain data that were not meaningful) using the formula:

$$\text{CAGR}(t_0, t_n) = \left(\frac{V(t_n)}{V(t_0)} \right)^{\frac{1}{t_n - t_0}} - 1;$$

$V(t_0)$: Start Value; $V(t_n)$: Finish Value; $t_n - t_0$: Number of Years

Table 1

Examples of Public Perception of Clinical Research in India.

Research Element	Perceptions	Source	Potential Implications/Consequences
	Negative		
Human participation	"Human guinea pigs"	Allahabad High Court [22]; PARTAKE survey [16]	Indians are exploited by foreign and rich industry entities for financial gain [23].
	Exploitation of vulnerable populations (illiterate or impoverished) [24]	Petition of Supreme Court [25]	Clinical trial applications put "on hold" amid revision of the regulatory system [19]
Adverse events	Violation of "right to live" under the constitution	Allahabad High Court [22]	Proposal to prosecute trial-related adverse events under the Indian Penal Code
	Unnecessary and exploitative	Media [26]; activists; surveys [27]; government compensation committee [28]	Adverse events are always due to trial participation and therefore should be compensated for; hold on clinical trials; withdrawal of drugs with favorable benefit/risk ratios [29]
Placebo assignment	Violation of the right to effective treatments	Government compensation scheme [30]	Proposal to compensate study participants for lack of therapeutic effect [30]
Informed consent	The process is not "informed" and "consent" cannot be assumed; consequence of paternalistic model of health care [31]	National Human Rights Commission [32], media [33,34], activists, PARTAKE survey [16]	Addition of audio-visual recording to informed-consent process [35]
	Positive		
Medical knowledge	Enhancing public health	Surveys [16,27]	Large majority endorses research
Human participation	Voluntarism	Surveys [16,27]	Majority interested in participating in research
	Altruism	Surveys [16,27]	Majority endorses altruism as the only valid motivation to participate in research

PARTAKE, Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment.

Table 2

Events Related to Standards of Clinical Research in India.

Event	Description	Impact	Notes
Deaths in HPV vaccine study	4 teenage girls die during vaccine trial [41]	Foreign sponsors (Gates Foundation, PATH) blamed for using Indians as “guinea pigs” [41]	A government-commissioned committee confirmed the deaths were not related to the vaccine [41]
CDSCO report	Government report finds deficiency in enforcement of regulation [40]	Activist protests, Supreme Court intervention, regulatory overhaul, hold on clinical trial approvals [18,19,30]	“Collusion” of regulators with industry sponsors is decried in the media; it is inferred by the identification of copycat letters sent by physician experts to the regulators in support of pharmaceutical clinical trial applications
NGO petitions	Requesting inquiry into the small number of trial adverse events and deaths resulting in compensation [33]	Leading to Supreme Court January 2013 decision (see below)	
Supreme Court decision	Petitioned by activists to investigate compensation for trial-related adverse events and deaths	Regulatory overhaul; 3-month hold on clinical trial application approval [19,25]	
NIH trials in India “on hold”	June 2013 announcement amid perceived regulatory and legal uncertainties [42]	Reduction in the amount of clinical research [19,43]	
FDA inspections	FDA issues warning letters to Ranbaxy, Wockhardt, and Jubilant	Diminished confidence in Indian pharmaceutical industry	Quotes from FDA inspectors: <ul style="list-style-type: none"> • “submitted untrue statements of material fact” [44] • “concerns about integrity of all data” [45] • “innocent ignorance, surprising sloppiness, malicious malfeasance” (HRPP conference, 2013)
Quintiles closing early-phase unit	Collaboration with Apollo Hospitals, Hyderabad—opened in 2010	One of only 2 early-phase units with international collaboration	Closed due to “challenging external business environment” [46]
Compensation schemes	Key feature of activist and judicial demands: compensation for adverse events and lack of therapeutic effect; ethics committees responsible for determining liability in clinical trials	Initial compensation proposals prompt sponsor and investigator reluctance to conduct trials [18]	Unresolved issues: determination of adverse-event causality; expectation of efficacy in clinical research; liability of placebo assignment; ethics committee resources and expertise to determine liability in clinical trials [38,30,47]

FDA, U.S. Food and Drug Administration; HPV, human papillomavirus; HRPP, human research protection program; NGO, non-governmental organization; NIH, U.S. National Institutes

Table 3

AAHRPP Domains and Standards.

Domain	Standards
Domain I: Organization	I-1: Organization has systemic and comprehensive human protection program
	I-2: Adequate resources exist for program implementation
	I-3: Transnational research activities are consistent across sites and respectful of local laws and cultural context
	I-4: There is adequate response to research participant concerns
	I-5: There are performance metrics and continuous process improvement
	I-6: Financial conflicts of interest are identified and managed to minimize impact
	I-7: There are policies and procedures governing use of investigational products
	I-8: There is collaboration with public, industry, and public stakeholders
Domain II: IRB or EC	II-1: Structure and composition of IRB/EC is appropriate to the amount and nature of the research reviewed
	II-2: IRB/EC evaluates each research protocol to ensure protection of participants
	II-3: Approved protocols abide by applicable laws and regulations
	II-4: Additional protection is provided to vulnerable research participants
	II-5: IRB/EC maintains documentation of its activities
Domain III: Researcher and research staff	III-1: Adherence to ethical principles and rights and welfare of research participants are primary concerns when designing study
	III-2: Researchers and staff meet all regulatory requirements and applicable laws

Adapted from: aahrpp.org [60]

EC, ethics committee; IRB, institutional review board.

Table 4

PARTAKE Program Steps.

	Steps	Description
Step 1	PARTAKE survey of knowledge and perceptions of clinical research	Public survey to assess knowledge and perceptions of clinical research and inform education, public awareness, and participant protection programs
Step 2	Stakeholder collaborations	Collaborations with industry, health care providers, academia, regulatory, patient advocacy groups, media, and the public at large [68]
Step 3	Development of awareness and engagement programs	Educational programs will be created to address the knowledge and awareness gaps identified in the survey
Step 4	Research on PARTAKE impact	Research on impact of PARTAKE educational programs on public knowledge and awareness of clinical research
Step 5	Research on PARTAKE impact on clinical research	Research on impact of changing public knowledge, awareness, and attitudes on clinical research
Step 6	Enhancing clinical research programs	Development of “participant protection” and “public-friendly” clinical research programs
Step 7	Development of an endorsement and rating/scoring program	Establishing a rating/scoring program that includes representatives of all stakeholders involved in clinical research—to grade research operations for their “participant protection” and “public-friendly” properties and establish a process for endorsement and improvement of research operations

PARTAKE, Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment.

Table 5

Challenges Facing PARTAKE Initiative and Proposed Solutions.

Challenges	Solutions
Lack of public trust in investigators, sponsors, and regulators	Engage the public/community; invite patients/public to participate in clinical research decision-making; empower, partner, and establish transparency in clinical research operations; establish research participant bill of rights
Fragmentation of the research environment	Establish a comprehensive public relations strategy; improve communication amongst stakeholders; use common language; engage the media; hold "open-house" activities; engage community advocates
Myths and misconceptions	Increase awareness, educate, and reduce stigma; establish community advocates (members of the community who are informed about research and motivated to bridge the gap between the community and the research establishment)
Funding	Establish a self-sustaining model; identify partners and sponsors; provide services to research sites and activist organizations; apply for grants from government, NGO, and industry groups

PARTAKE, Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment; NGO, non-governmental organization